Dr. Luis Miguel Zetina. Médico y Cirujano .
Especialista en Medicina Interna. Hematologia Clinica y Oncologia Medica
Presidente de la Asociación Centroaméricana y del Caribe de Oncología
Presidente de Asociacion Guatemalteca de Hemato-Oncologia
Entrenamiento en investigación:
1.Good Clinical Practices Course. Antigua Guatemala. 22-23. April 2004
2.First Course of Clinical Investigation. Panamá. August 7-9, 2003.
3.Good Clinical Practices Course. Basic I. ICIC. Costa Rica. April 2001.
4.Evidence Based Medicine Courses. Guatemala. July 2001.
Investigador principal:
2002- a la fecha:
a.(CHAT) An open-label, randomized phase II study of Herceptin (Trastuzumab). Taxotere (docetaxel) and Xeloda (capecitabine) in combination, versus Herceptin (Trastuzumab) plus Taxotere (docetaxel), in patients with advanced and or metastatic breast cancers that overexpress HER2.
b.(HERA) A randomized three-arm multi-centre comparison of 1 year and 2 years or Herceptin versus no Herceptin in women with HER2-positive primary breast cancer who have completed adjuvant chemotherapy.
c.A 2X2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (“XELOX”) with/without Intravenous Bevacizumab (Q3W) versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin with Intravenous Oxaliplatin (2Qw) (“FOLFOX-4”) with/without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients with Metastic Colorectal Cancer.
d.BO 18040 “ Randomized two arm, placebo controlled study to compare the efficacy of intravenous loading doses followed by maintenance treatment with intravenous ibandronic acid versus zolendrónico acid in pacients with skeletal metastases experiencing moderate to severe pain.”
e.ToGA: treatment of advanced gastric Adenocarcinoma in ptes with HER 2 positive with cisplatin plus capecitabine or 5fu With Herceptin. Vrs cisplatin plus 5 FU alone
f.AVFg: Bevacizumab or no Avastin and capecitabine in metastatic breast cancer in first line treatment after 1 year in complete remmision
g. FACT .Faslodex and combination treatment y advanced breast cancer in first relapsed breasy cancer ptes.
